Australia Markets closed

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8100-0.0619 (-7.10%)
At close: 04:00PM EDT
0.8500 +0.04 (+4.94%)
After hours: 05:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8719
Open0.8800
Bid0.7585 x 100
Ask0.8651 x 100
Day's range0.8005 - 0.9200
52-week range0.7820 - 4.2900
Volume166,472
Avg. volume100,932
Market cap43.988M
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    CytoSorbents Reports First Quarter 2024 Results

    Product Sales up a robust 14% over prior year, and a significant 22% sequentiallyWe believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood pu

  • GlobeNewswire

    CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

    PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it will host a virtual Key Opinion Leader and Analyst-Investor Day on Monday, May 6, 2024 from 11:30 AM to 1:30 PM ET. To register, click here. The program will cover the significant challenge of severe perio

  • GlobeNewswire

    CytoSorbents to Report First Quarter 2024 Operating and Financial Results

    PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024. CytoSorbents’ management will host a live conference call and presentation webcast and a question and answer session starting at 4:30PM EDT the same day. Webcast D